DelNS1-2019-nCoV-RBD-OPT
Vaccine candidate against COVID-19 / From Wikipedia, the free encyclopedia
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.[2][3][4]
Quick Facts Vaccine description, Target ...
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | Pneucolin |
Other names | DelNS1-nCoV-RBD LAIV[1] |
Routes of administration | Intranasal |
Close
On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.[5]